• TransCode Therapeutics reported patent progress in Australia, citing acceptance of an application covering siRNA cancer therapies using nanoparticle delivery.
• Japan granted a patent covering RNA immunomodulatory compositions designed to activate innate immune pathways such as RIG-I in tumors.
• Australian application covers iron-oxide, dextran-coated nanoparticles with covalently linked siRNA, spanning broad oncology use.
• Japanese claims include approaches aimed at cancers expressing miR-21, including nanoparticle-enabled delivery systems.
• Australian patent, if granted, is expected to expire on Sept. 6, 2039.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609220804PR_NEWS_USPR_____NE53047) on September 22, 2026, and is solely responsible for the information contained therein.